|
|
News Breaks | | | | January 18, 2013 | | 17:14 EDT |  | CVM | CEL-SCI files $50M mixed securities shelf
| |
|
News For CVM From The Last 14 Days Check below for free stories on CVM the last two weeks. |
|
|
| May 6, 2013 | | 08:34 EDT |  | CVM | CEL-SCI presents data on LEAPS vaccine
CEL-SCI Corporation announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis using the LEAPS technology, which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics. The study was conducted in collaboration with Dr. Tibor Glant’s research team at Rush University Medical Center. The efficacy study evaluated the LEAPS vaccine’s effect in the Proteoglycan induced arthritis model of RA with a dominant T helper 1 cytokine profile. The PGIA model was developed and has been studied extensively in Dr. Glant’s laboratory at Rush University Medical Center for over 25 years and is considered to be closely related to the human condition of many RA patients. The PGIA model exhibits rheumatoid factor and RA-specific antibodies not seen in other RA models. | |
|
|
|
|
|
|
